Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Structure Therapeutics
Biotech
Metsera sale architect swings to Structure—Chutes & Ladders
Metsera acquisition architect swings to Structure. Vir CMO exits after less than 2 years. Leal reels in Big Pharma vets to exec team.
Darren Incorvaia
,
Zoey Becker
,
Will Maddox
Apr 17, 2026 10:10am
After $2.1B Novo deal, Vivtex is just getting started
Apr 8, 2026 8:00am
Structure touts 16% weight loss 'highest efficacy' for oral GLP1
Mar 16, 2026 10:02am
Roche commits $100M to keep its GLP-1 Structure sound
Jan 6, 2026 10:21am
Wave, Structure stocks double on obesity data readouts
Dec 8, 2025 10:50am
2 Kite vets fly over to Kyverna Therapeutics—Chutes & Ladders
Sep 20, 2024 8:30am